Document ID: chunk:federal_register_of_legislation:F2023L01440:reg:9:p5
Version: federal_register_of_legislation:F2023L01440
Segment Type: reg
Provision Reference: reg 9 (pt 5/6)
Character Range: 18685–21617

Dictionary.
(47)      being obese at the time of the clinical worsening of anxiety disorder;
Note: being obese is defined in the Schedule 1 – Dictionary.
(48)      inability to undertake physical activity greater than 3 METs for a continuous period of at least the 3 months before the clinical worsening of anxiety disorder;
Note: MET is defined in the Schedule 1 – Dictionary.
(49)      having another medical condition, including an endocrine, cardiovascular, respiratory, metabolic, infectious or neurological disorder, where the signs or symptoms of anxiety are directly related to the pathological process of the medical condition and not solely due to its psychosocial stress effects, at the time of the clinical worsening of anxiety disorder;
(50)      taking mefloquine within the 2 days before the clinical worsening of anxiety disorder, where anxiety disorder persists after the discontinuation or tapering of mefloquine therapy;
(51)      using a psychoactive substance from the specified list of psychoactive substances at an intoxicant dose within the 2 days before the clinical worsening of anxiety disorder;
Note: intoxicant dose and specified list of psychoactive substances are defined in the Schedule 1 – Dictionary.
(52)      taking a drug that cannot be ceased or substituted in the long term and which is associated in the individual with the worsening of anxiety symptoms during drug therapy and either:
(a)          the improvement of anxiety symptoms within days or weeks of discontinuing or tapering drug therapy; or
(b)          the worsening of anxiety symptoms on rechallenge with the same drug;
where the drug was being taken within the 2 days before the clinical worsening of anxiety disorder;
(53)      using a psychoactive chemical or substance at an intoxicant dose, which is associated in the individual with the worsening of anxiety symptoms, and where the psychoactive chemical or substance was being taken within the 2 days before the clinical worsening of anxiety disorder;
Note: intoxicant dose is defined in the Schedule 1 – Dictionary.
(54)      having ceased or reduced therapeutic or illicit drug use or other substance use within the 10 days before the clinical worsening of anxiety disorder;
(55)      having periodic, heavy alcohol consumption for the 3 months before the clinical worsening of anxiety disorder;
Note: periodic, heavy alcohol consumption is defined in the Schedule 1 – Dictionary.
(56)      having an alcohol use disorder or a substance use disorder at the time of the clinical worsening of anxiety disorder;
(57)      having smoked tobacco products in an amount of at least 0.5 pack-years before the clinical worsening of anxiety disorder, and if smoking has ceased before the clinical worsening of anxiety disorder, then that worsening occurred within 3 months of cessation;
Note: one pack-year is defined in the Schedule 1 - Dictionary.
(58)      having an episode of